SAMSUNG ELECTRONICS CO LTD invested $175 million in the privately held Element Biosciences on Tuesday, June 9, to become the genetics firm's largest shareholder. This upsized Series E funding follows a $277 million Series D round completed in July 2024. The deal integrates DNA sequencing with SAMSUNG ELECTRONICS CO LTD's AI and medical device capabilities to target the genetic diagnostics market.
Samsung Becomes Top Shareholder in US Genetics Firm
Samsung Electronics has invested 175 million dollars in San Diego-based Element Biosciences to deepen cooperation in genetic diagnostics and personalized medicine. The funding will support the commercialization of benchtop gene-sequencing equipment and the development of future digital health technologies.
Xurve View
洞察:
Xurve View











